Dallas, Texas--(Newsfile Corp. - September 24, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX): Stonegate Capital Partners initiates their coverage on Medicus Pharma Ltd. (NASDAQ: MDCX). Medicus advanced several strategic initiatives in 2Q25 as it builds a diversified portfolio of clinical and pre-clinical assets. The Company completed the acquisition of Antev Limited, expanding its therapeutic pipeline into dermatology and infectious diseases, complementing its lead microneedle patch technology for skin cancer. In addition, Medicus entered into a Memorandum of Understanding (MoU) with Helix Nanotechnologies to co-develop thermostable vaccines for infectious diseases, a collaboration that addresses critical global healthcare challenges tied to cold-chain limitations. Financially, the Company secured an $8.0M non-dilutive debenture financing, strengthening its balance sheet and extending cash runway while minimizing dilution for existing shareholders. These milestones have highlighted the Company's strategy of combining organic development with opportunistic acquisitions to accelerate the advancement of its therapeutic assets.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Medicus Pharma acquired Antev Limited in 2Q25, adding dermatology and infectious disease assets.
- MDCX closed an $8M debenture; with cash of $9.7M at 2Q25 extends runway into 2026.
- Entered into a MoU with Helix Nanotechnologies to develop thermostable infectious disease vaccines.
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/267748
